VR 876

Drug Profile

VR 876

Alternative Names: Breelib; VR-876

Latest Information Update: 28 Dec 2016

Price : $50

At a glance

  • Originator Activaero GmbH
  • Developer Bayer; Vectura
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Lung disorders
  • Discontinued Pulmonary hypertension

Most Recent Events

  • 22 Dec 2016 Registered for Lung disorders in European Union (Inhalation)
  • 06 Oct 2015 Discontinued - Phase III for Pulmonary hypertension in World (unspecified route)
  • 02 Oct 2015 Phase III clinical trials in Lung disorders in World (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top